SB 202026

THERAPEUTICS Sabcomeline Memric Small Molecule Other Neurotransmitters SB 202026 is a selective muscarinic M1 receptor partial agonist. Alzheimer's Disease Discontinued Breaking News http://www.alzforum.org/drg/drc/detail.asp?id=80

Sabeluzole

THERAPEUTICS R58735 Small Molecule Unknown Sabeluzole has been reported to reduce glutatmate toxicity in part by reducing NMDA-induced inward current (Van der Valk et al., 1993). It also has been shown to affect cytoskeletal stability (Geerts et al., 1996) and tau exp

Rosiglitazone

THERAPEUTICS 5-[[4-[2-(methyl-pyridin-2-yl-amino)ethoxy]phenyl]methyl]thiazolidine-2,4-dione, AVANDIA® GlaxoSmithKline (GSK) Rosiglitazone maleate Avandia Small Molecule Other A dozen clinical studies have evaluated rosiglitazone in AD. Starting in 1999, a pilot study

Rofecoxib

THERAPEUTICS Merck Vioxx™ Small Molecule Inflammation Three clinical trials of rofecoxib in Alzheimer's disease have been conducted. In 2000 and 2001, the Alzheimer's Disease Study Group conducted a 40-center trial that compared one year of treatment with 25

RG3487

THERAPEUTICS N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-1H-indazole-3-carboxamide hydrochloride RO5313534 MEM 3454 Small Molecule Cholinergic System Roche licensed this therapeutic from Memory Pharmaceuticals Corp. In 2006, Memory Pharmaceuticals had announced positive pre

Resveratrol

THERAPEUTICS trans-3,4',5-trihydroxystilbene Small Molecule Supplement, Dietary Other Between 2008 and 2010, a Phase 3 trial at the Veterans Affairs Medical Center in the Bronx, New York, evaluated a one-year course of treatment with a liquid formulation of resve

PRX-03140

THERAPEUTICS 7-isopropyl-6-oxo-5(3-piperidin-1-yl-propylcarbamoyl)-6,7-dihydro-thieno[2,3-b]pyridine-4-olate Epix Pharmaceuticals Potassium salt Small Molecule Other 5-HT4 receptor agonists augment neuronal acetylcholine release (Ansanay et al., 1995; Torres et al., 1

Synuclein Resists and Disrupts Autophagy

RESEARCH NEWS 2013-04-12 Research News Could cranking up a cellular waste removal system help rid the brain of misfolded α-synuclein, the principle component of Lewy bodies found in neurodegenerative disorders such as Parkinson’s disease (PD)? Perhaps not, suggest researchers led

PAPER Petit GH, Berkovich E, Hickery M, Kallunki P, Fog K, Fitzer-Attas C, Brundin P